ClinicalTrials.gg
Not yet recruitingNCT07234474Updated Sep 30, 2026

A Phase I Study of YK012 in Primary Membranous Nephropathy

A Phase 1 interventional study of YK012 in Primary Membranous Nephropathy, sponsored by Excyte Biopharma Ltd. Not yet recruiting. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Excyte Biopharma Ltd · Phase 1, Interventional, and Treatment

Updated Sep 30, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics(PK), pharmacodynamics (PD), immunogenicity, and preliminary efficacy of YK012 in participants with primary membranous nephropathy (pMN).

02

Conditions studied

  • Primary Membranous Nephropathy
03

In context

Glomerulonephritis, Membranous

146 studies on the registry are indexed under Glomerulonephritis, Membranous; 60 are open to participants now.

This study's planned enrollment of 66 is above the median of 46 across 105 interventional studies indexed under Glomerulonephritis, Membranous.

Browse Glomerulonephritis, Membranous studies →

Lead sponsor

Excyte Biopharma Ltd is the lead sponsor of 7 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-80 (inclusive), both gender.
  • Diagnosed with primary (idiopathic) membranous nephropathy by renal within 10 years.
  • Participants who meet the criteria of very high-risk primary (idiopathic) membranous nephropathy based on 2021 Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for the Management of Glomerular Diseases and who have failed available therapies for the treatment of pMN.
  • estimated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula is ≥45 mL/min/1.73 m².
  • If taking angiotensin-converting enzyme inhibitor (ACEI), angiotensin II receptor blocker (ARB), or Sodium-Glucose Co-Transporter 2 (SGLT-2) inhibitor, the medication dosage must have been stable (≤50% change in dose) for at least 4 weeks prior to screening and continue being stable prior to the initiation of the product.
  • Laboratory tests within 7 days prior to enrollment meet the pre-defined criteria.
  • Be able to understand and voluntarily participate in this clinical trial with written signed and available for scheduled visits, treatments, examinations, and other study procedures.

Exclusion criteria

Exclusion Criteria:

  • Diagnosed with secondary membranous nephropathy.
  • Any prior receipt of protocol-specified pharmacological treatment for membranous nephropathy.
  • History of malignant tumor within 5 years prior to screening.
  • Poorly controlled hypertension.
  • Participants with severe renal insufficiency who have received or require dialysis or kidney transplantation within 6 months prior to the initiation of the product.
  • History of diabetic nephropathy confirmed by renal .
  • History of severe or chronic infections within 6 months prior to screening or currently infection requiring systemic antibiotic or antiviral therapy.
  • History of cardiovascular event leading to hospitalization within 6 months prior to screening.
  • Other severe or poorly controlled diseases that may affect the protocol compliance or efficacy assessments.
  • Have active tuberculosis with clear evidence of infection.
  • History of substantial organ or bone marrow transplantation.
  • Received , underwent major surgery, or participated in other clinical trials and applied any other study drugs within 28 days prior to the initiation of the investigational product.
  • surface antigen (HBsAg) positive, or hepatitis B core antibody (HBcAb) positive with hepatitis B virus (HBV) DNA quantification ≥ 1×103 copies/L or ≥ 50 IU/L (HBcAb positive participants require regular HBV DNA testing); virus (HCV) antibody positive; (HIV) seropositive; Syphilis helical antibody positive.
  • Peripheral blood \< 200 cells/μL.
  • The peripheral blood B-cell count is below the lower limit of normal.
  • Known to any of the ingredients of YK012.
  • Female participants who are pregnant or breastfeeding, or women of (WOCBP) who have a positive pregnancy test result at screening; or those who plan to have children during the trial period and for 12 months after the end of the trial, and those who are unwilling to use one or more physical methods during the trial period and for 12 months after the end of the trial.
  • Other conditions that the investigator considers inappropriate for participation in this trial.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
66 participants (estimated)

Study arms

  • Experimental
    Ia: YK012

    Participants with primary membranous nephropathy will receive ascending doses of YK012 infusion to evaluate the safety and tolerability of YK012, and to determine the Maximum Tolerated Dose (MTD) and Recommended Dose for Expansion (RDE)

    Drug: YK012

  • Experimental
    Ib: YK012

    Participants will receive 2 different doses of YK012 infusion to evaluate the safety and tolerability of YK012 in participants with primary membranous nephropathy and to establish the Recommended Phase II Dose (RP2D).

    Drug: YK012

Interventions

  • DrugYK012

    YK012 is a bispecific antibody targeting CD19 on B cells and CD3 on T cells leading to T cell-mediated cytotoxicity of malignant B cells

06

What researchers measure

Primary outcomes

  1. Ia: Dose-Limiting Toxicity (DLT)

    Time frame: up to 28 days after the first dose

  2. Adverse Event (AE)

    Time frame: From the first induction to the end of the trial at 53 weeks

  3. Severe Adverse Event

    Time frame: From the first induction to the end of the trial at 53 weeks

Secondary outcomes

  1. Area under the concentration-time curve (AUC0-t)

    Time frame: From 1 hour before the first infusion of YK012 to the end of trial at 53 or 77 weeks

  2. Area under the concentration-time curve from time 0 to ∞ (AUC0-∞)

    Time frame: From 1 hour before the first infusion of YK012 to the end of trial at 53 or 77 weeks

  3. Maximum plasma concentration (Cmax)

    Time frame: From 1 hour before the first infusion of YK012 to the end of trial at 53 or 77 weeks

  4. Time to reach maximum concentration (Tmax)

    Time frame: From 1 hour before the first infusion of YK012 to the end of trial at 53 or 77 weeks

  5. Half-life (t1/2)

    Time frame: From 1 hour before the first infusion of YK012 to the end of trial at 53 or 77 weeks

  6. Apparent clearance (CL)

    Time frame: From 1 hour before the first infusion of YK012 to the end of trial at 53 or 77 weeks

  7. apparent volume of distribution (Vd)

    Time frame: From 1 hour before the first infusion of YK012 to the end of trial at 53 or 77 weeks

  8. Minimum plasma concentration (Cmin)

    Time frame: From 1 hour before the first infusion of YK012 to the end of trial at 53 or 77 weeks

  9. Time to onset and duration of peripheral blood B-cell and B-cell subset depletion

    Time frame: From 1 hour before the first infusion of YK012 to the end of trial at 53 or 77 weeks

  10. Changes in peripheral blood Natural Killer (NK) cells

    Time frame: From 1 hour before the first infusion of YK012 to the end of trial at 53 or 77 weeks

  11. Changes in peripheral blood T cells and T cell subsets (CD4+ T cells, CD8+ T cells)

    Time frame: From 1 hour before the first infusion of YK012 to the end of trial at 53 or 77 weeks

  12. The profile of cytokine changes

    Time frame: From 1 hour before the first infusion of YK012 to the end of trial at 53 or 77 weeks

  13. Positive rates of blood anti-drug antibody (ADA) and neutralizing antibody (Nab)

    Time frame: From 1 hour before the first infusion of YK012 to the end of trial at 53 or 77 weeks

  14. Changes from baseline in 24-hour urine protein during the trial period

    Time frame: From screening to the end of the trial at 53 or 77 weeks

  15. Changes from baseline in estimated glomerular filtration rate (eGFR) during the trial period

    Time frame: From screening to the end of the trial at 53 or 77 weeks

  16. Changes from baseline in anti-phospholipase A2 receptor (PLA2R) antibody titer during the trial period

    Time frame: From screening to the end of the trial at 53 or 77 weeks

  17. Proportion of participants achieving overall renal remission (ORR)

    Time frame: From screening to the end of the trial at 53 or 77 weeks

  18. Proportion of participants achieving Complete Response (CR) and Partial Response (PR)

    Time frame: From screening to the end of the trial at 53 or 77 weeks

  19. Proportion of participants achieving immunological remission

    Time frame: From screening to the end of the trial at 53 or 77 weeks

  20. Time to achieve CR

    Time frame: From screening to the end of the trial at 53 or 77 weeks

  21. Time to achieve ORR

    Time frame: From screening to the end of the trial at 53 or 77 weeks

  22. Duration of CR

    Time frame: From screening to the end of the trial at 53 or 77 weeks

  23. Duration of ORR

    Time frame: From screening to the end of the trial at 53 or 77 weeks

  24. Proportion of participants with treatment failure

    Time frame: From screening to the end of the trial at 53 or 77 weeks

  25. Proportion of participants who relapsed

    Time frame: From screening to the end of the trial at 53 or 77 weeks

07

Study locations

No study locations are listed for this record.

08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Sep 2027; primary completion for Oct 2028, 13 months later.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 30, 2026: start Oct 2026 → Sep 2027, primary completion Nov 2027 → Oct 2028 and completion Feb 2028 → Jan 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2025
First posted
Nov 18, 2025
StartEst.
Sep 2027was Oct 2026
Primary completionEst.
Oct 2028was Nov 2027
CompletionEst.
Jan 2029was Feb 2028
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Oct 2026→Sep 2027
Sep 30, 2026
Primary completion
Nov 2027→Oct 2028
Sep 30, 2026
Study completion
Feb 2028→Jan 2029
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    Start date Oct 2026→Sep 2027
    Primary completion Nov 2027→Oct 2028
    Study completion Feb 2028→Jan 2029
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07234474
Lead sponsor
Excyte Biopharma Ltd
Responsible party
Sponsor
First posted
Nov 18, 2025
Start date
Sep 2027 (estimated)
Primary completion
Oct 2028 (estimated)
Completion
Jan 2029 (estimated)
Last update
Sep 30, 2026

Study contacts

Minghui Zhao, M.D.
Contact
mhzhao@bjmu.edu.cn
+86-010-83572388
Minghui Zhao
principal investigator · Peking University First Hospital

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: YK012

Start the discussion